| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Department of Endocrinology and Metabolism, Toranomon Hospital and Okinaka Memorial Institute for Medical Research (K.N., T.K., T.M.), Tokyo 105-8470, Japan; the Department of Molecular Life Science, Tokai University School of Medicine (T.N., H.I.), Isehara 259-1100; and the Hyogo Red Cross Blood Center (Y.N.), Kobe 651-0062, Japan
Address all correspondence and requests for reprints to: Koji Nakanishi, M.D, Department of Endocrinology and Metabolism, Toranomon Hospital, 22-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan.
The aim of this study is to identify insulin-dependent diabetes mellitus (IDDM)-susceptible HLA antigens in IDDM patients who do not have established risk allele, HLA-DQA1*0301, and analyze relationship of these HLA antigens and the degree of ß-cell destruction.
In 139 Japanese IDDM patients and 158 normal controls, HLA-A, -C, -B,
-DR and -DQ antigens were typed. Serum C-peptide immunoreactivity
response (
CPR) to a 100-g oral glucose load
0.033 nmol/l was
regarded as complete ß-cell destruction.
All 14 patients without HLA-DQA1*0301 had HLA-A24, whereas only 35 of
58 (60.3%) normal controls without HLA-DQA1*0301 and only 72 of 125
(57.6%) IDDM patients with HLA-DQA1*0301 had this antigen (Pc =
0.0256 and Pc = 0.0080, respectively).
CPR in IDDM patients
with both HLA-DQA1*0301 and HLA-A24 (0.097 ± 0.163 nmol/L,
mean ± SD, n = 65) were lower than in IDDM
patients with HLA-DQA1*0301 only (0.219 ± 0.237 nmol/L, n =
45, P < 0.0001) and in IDDM patients with HLA-A24
only (0.187 ± 0.198 nmol/L, n = 14, P =
0.0395).
These results indicate that both HLA-DQA1*0301 and HLA-A24 contribute susceptibility to IDDM independently and accelerate ß-cell destruction in an additive manner.
This article has been cited by other articles:
![]() |
K. Nakanishi and H. Inoko Combination of HLA-A24, -DQA1*03, and -DR9 Contributes to Acute-Onset and Early Complete {beta}-Cell Destruction in Type 1 Diabetes: Longitudinal Study of Residual {beta}-Cell Function Diabetes, June 1, 2006; 55(6): 1862 - 1868. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takaki, M. P. Marron, C. E. Mathews, S. T. Guttmann, R. Bottino, M. Trucco, T. P. DiLorenzo, and D. V. Serreze HLA-A*0201-Restricted T Cells from Humanized NOD Mice Recognize Autoantigens of Potential Clinical Relevance to Type 1 Diabetes. J. Immunol., March 1, 2006; 176(5): 3257 - 3265. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |